Available Technology

Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel

This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. Unlike culture and serological tests requiring 5 to 14 days for completion, CDC researchers developed a rapid, accurate assay, which is easily adapted to kit form. This assay also requires less labor input than immunoassays. These methods can be used to quickly identify a broad variety of influenza types and subtypes, including viruses that may be involved in pandemics (such as H5N1, for example).
Patent Abstract: 
This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. Unlike culture and serological tests requiring 5 to 14 days for completion, CDC researchers developed a rapid, accurate assay, which is easily adapted to kit form. This assay also requires less labor input than immunoassays. These methods can be used to quickly identify a broad variety of influenza types and subtypes, including viruses that may be involved in pandemics (such as H5N1, for example).
Benefits 
Already FDA approved -Especially useful for H5N1 screening -Sensitive detection -Specific discrimination of influenza subtypes -Easily formatted as kit or array -Faster than culturing and serological identification methods -Less laborious and more objective than immunoassays
applications 
Inventors: 

Alexander Klimov

Stephen Lindstrom (CDC)

Patent Number: 
12/191,186 US Application No. 13/554,782 US Applic
Internal Laboratory Ref #: 
E-331-2013/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin